SCHEMBL3582249

SCHEMBL3582249

Fc1ccc(-c2coc(C3CCCNC3)n2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.47
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
KCNH2 Q12809 1/20 0.39
CCNT1 O60563 4/20 0.39
CDK9 P50750 4/20 0.39
CHEK1 O14757 3/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
MAP4K4 O95819 2/20 0.38
INSR P06213 2/20 0.38
CSF1R P07333 2/20 0.38
PIM1 P11309 2/20 0.38
CLK2 P49760 2/20 0.38
IRAK1 P51617 2/20 0.38
MAP4K2 Q12851 2/20 0.38
DYRK1A Q13627 2/20 0.38
MINK1 Q8N4C8 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3582248 1.00 MPO (0.47) MPODRD2HTR2AHTR2CKCNH2
SCHEMBL3583291 0.85 ACP1 (0.41) MPOCHEK1CCNA2CDK2CCNA1
SCHEMBL3583286 0.85 ACP1 (0.41) MPOCHEK1CCNA2CDK2CCNA1
Hydrochloric Acid SCHEMBL4599388 0.84 ACP1 (0.40) MPOCHEK1CCNA2CDK2CCNA1
SCHEMBL3581077 0.83 MAPK11 (0.47) MPODRD2HTR2AHTR2CKCNH2
SCHEMBL3581075 0.83 MAPK11 (0.47) MPODRD2HTR2AHTR2CKCNH2
Hydrochloric Acid SCHEMBL193070 0.78 CNR2 (0.44) MPO
Hydrochloric Acid SCHEMBL193069 0.78 CNR2 (0.44) MPO
SCHEMBL3582287 0.77 MPO (0.40) MPODRD2HTR2AHTR2CKCNH2
SCHEMBL3582283 0.77 MPO (0.40) MPODRD2HTR2AHTR2CKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089386-B1 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2012-08-08 EP disclosed
US-20100081690-A1 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2010-04-01 US disclosed
EP-2089386-A2 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2009-08-19 EP disclosed
WO-2008056259-A2 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081690-A1 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 MPO 3969/4885DRD2 141/4885HTR2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.